Analysis of reference range and influencing factors of tacrolimus blood concentration in children with Henoch-Schonlein purpura nephritis
- VernacularTitle:过敏性紫癜性肾炎患儿他克莫司血药浓度参考范围及影响因素分析
- Author:
Huiying LI
1
;
Fashuang LI
1
;
Linbo LI
1
;
Lilin ZHANG
1
Author Information
1. Dept. of Pharmacy，Children’s Hospital Affiliated to Kunming Medical University，Kunming 650228，China
- Publication Type:Journal Article
- Keywords:
tacrolimus;
Henoch-Schonlein purpura nephritis;
blood concentration;
influencing factors;
children
- From:
China Pharmacy
2025;36(8):975-980
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the reference range of tacrolimus blood concentration in children with Henoch- Schonlein purpura nephritis （HSPN） and analyze the factors affecting the blood concentration， in order to provide a reference for rational use of the drug in clinic. METHODS Clinical data of children with HSPN who were treated with tacrolimus and regularly monitored for blood concentration at the Children’s Hospital Affiliated to Kunming Medical University were retrospectively collected from January 2018 to January 2024. The threshold of effective concentration of tacrolimus was determined by the receiver operating characteristic curve of the subjects. The clinical efficacy of tacrolimus in different concentrations and the incidence of adverse drug reaction （ADR） were compared to determine the reference range of tacrolimus blood concentration. The factors influencing the blood concentration were analyzed by one-way and multiple linear regression. RESULTS A total of 97 pediatric patients were included， and their tacrolimus blood concentrations were monitored 203 times， the blood concentration was 4.26 （2.47， 6.34） ng/mL. The area under the receiver operating characteristic curve of the subjects was 0.723 （95%CI：0.596-0.850， P＜ 0.01）， which corresponded to an effective threshold of 2.19 ng/mL. The clinical efficacy in pediatric patients with tacrolimus blood concentrations of 3-＜5 ng/mL， 5-＜10 ng/mL， and ≥10 ng/mL was significantly higher than that of children with concentrations ＜3 ng/mL （P＜0.05）. Additionally， the overall incidence of ADR in children with concentrations of 5-＜10 ng/mL and ≥10 ng/mL was significantly higher than that in children with concentrations ＜3 ng/mL and 3-＜5 ng/mL （P＜0.05）. The impact of body mass index and CYP3A5 genotype on the blood concentration of tacrolimus was statistically significant （P＜0.05）. CONCLUSIONS When using tacrolimus to treat HSPN in children clinically， the reference range for blood concentration is 3 to 5 ng/mL； body mass index and CYP3A5 genotype are factors that influence the blood concentration of tacrolimus.
